Published in Int J Mol Sci on March 11, 2016
Açai (Euterpe oleracea Mart.) Upregulates Paraoxonase 1 Gene Expression and Activity with Concomitant Reduction of Hepatic Steatosis in High-Fat Diet-Fed Rats. Oxid Med Cell Longev (2016) 0.76
Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review. BMJ Open Gastroenterol (2017) 0.76
Nematodes and human therapeutic trials for inflammatory disease. Parasite Immunol (2016) 0.75
Nonalcoholic Fatty Liver Disease and Associated Metabolic Risks of Hypertension in Type 2 Diabetes: A Cross-Sectional Community-Based Study. Int J Endocrinol (2017) 0.75
A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Sci Rep (2017) 0.75
The relationship of nonalcoholic fatty liver disease and metabolic syndrome for colonoscopy colorectal neoplasm. Medicine (Baltimore) (2017) 0.75
E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6. Lipids Health Dis (2017) 0.75
Nonalcoholic fatty liver disease in long-term survivors of childhood-onset craniopharyngioma. Ann Pediatr Endocrinol Metab (2017) 0.75
NAFLD: Is There Anything New under the Sun? Int J Mol Sci (2017) 0.75
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature (2012) 10.74
Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med (2011) 10.33
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science (2006) 7.35
Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest (1999) 6.99
The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med (2005) 6.23
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology (2004) 5.83
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005) 5.11
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology (2010) 4.76
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab (2007) 4.51
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care (2007) 4.42
Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med (2010) 4.14
The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol (2007) 4.01
Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest (2007) 3.88
Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med (2004) 3.88
History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis (2001) 3.13
Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA (2015) 3.04
High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes (2002) 2.98
Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm (2006) 2.72
Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology (2008) 2.70
Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2014) 2.49
Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology (2015) 2.48
Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes (2005) 2.42
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A (2011) 2.39
Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes (2009) 2.36
PAI-1 in tissue fibrosis. J Cell Physiol (2012) 2.26
NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol (2009) 2.19
Gamma-glutamyltransferase and diabetes--a 4 year follow-up study. Diabetologia (2003) 2.14
Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond) (2009) 1.98
Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ (2010) 1.95
Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. J Biol Chem (2008) 1.94
Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int (2008) 1.90
Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci (2000) 1.85
Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology (1996) 1.83
Histological assessment of non-alcoholic fatty liver disease. Histopathology (2006) 1.80
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun (2014) 1.66
Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. J Hepatol (2014) 1.65
Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J (2008) 1.55
The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. J Hypertens (2010) 1.51
TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci U S A (2014) 1.49
Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther (2010) 1.46
The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol (2010) 1.45
Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity. J Biol Chem (2010) 1.44
Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab (2013) 1.44
Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism (2008) 1.43
Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab (2011) 1.38
Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol (2012) 1.37
PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther (2014) 1.37
Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr (1999) 1.35
Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol (2010) 1.34
Dissociating fatty liver and diabetes. Trends Endocrinol Metab (2012) 1.29
Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology (2010) 1.27
Adipose tissue dysfunction in nascent metabolic syndrome. J Obes (2013) 1.26
Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice. Diabetologia (2010) 1.25
Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract (2009) 1.18
Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroenterol Hepatol (2013) 1.17
Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care (2005) 1.14
How big a problem is non-alcoholic fatty liver disease? BMJ (2011) 1.13
Chronic inflammation: role of adipose tissue and modulation by weight loss. Curr Diabetes Rev (2006) 1.11
Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care (2012) 1.09
Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. J Pediatr Gastroenterol Nutr (2009) 1.09
The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. Clin Sci (Lond) (2009) 1.08
Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastroenterol (2011) 1.07
Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis (2014) 1.07
Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol (2012) 1.05
Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg (2006) 1.03
Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol (2001) 1.02
Longitudinal increase in gamma-glutamyltransferase within the reference interval predicts metabolic syndrome in middle-aged Korean men. Metabolism (2009) 0.97
Pathophysiology of fatty acid oxidation disorders. J Inherit Metab Dis (2009) 0.97
Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line. Metabolism (2006) 0.96
The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-year's prospective cohort study. Atherosclerosis (2013) 0.95
Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol (2014) 0.94
PNPLA3/adiponutrin functions in lipid droplet formation. Biol Cell (2013) 0.92
The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis. Hepatology (2015) 0.92
Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. J Hepatol (2014) 0.92
Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab (2013) 0.91
Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol (2011) 0.90
Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol (2014) 0.89
Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg (2007) 0.87
Phosphatidylcholine protects against steatosis in mice but not non-alcoholic steatohepatitis. Biochim Biophys Acta (2011) 0.86
Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders. Clin Exp Hypertens (2009) 0.86
Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ Open (2015) 0.86
Dissociation between fatty liver and insulin resistance: the role of adipose triacylglycerol lipase. Diabetologia (2010) 0.83
Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. Diabetes Metab Res Rev (2010) 0.83
Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan. Gut Liver (2016) 0.83
A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study. PLoS One (2015) 0.82
Prediction of metabolic syndrome by non-alcoholic fatty liver disease in northern urban Han Chinese population: a prospective cohort study. PLoS One (2014) 0.82
Plasma proteome analysis in diet-induced obesity-prone and obesity-resistant rats. Proteomics (2010) 0.82
Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. Atherosclerosis (2015) 0.82
Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension. J Korean Med Sci (2014) 0.80
Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism. Cell Metab (2015) 0.79
Prevalence of nonalcoholic fatty liver disease in subjects with metabolic syndrome. Cir Cir (2012) 0.77